Monday, 06 May 2024
Protagonist Therapeutics Inc
-
Overlay
-
Indicators
-
Settings
-
Period
Analysts expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to report $-0.99 EPS on March, 6.They anticipate $0.32 EPS change or 47.76 % from last quarter's $-0.67 EPS.
more»
22:33 | 2/2/18
StockNewsTimes
Protagonist Therapeutics logo Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of the firm's stock in a transaction on Tuesday, January 16th.
more»
01:56 | 1/2/18
PR Newswire
The alpha-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist PTG-200 is currently being studied in a Phase 1 clinical trial in ...
more»
Protagonist is also expected to release phase 1 results for PTG-200 in Crohn's disease in the second quarter, and the firm's partnership with Johnson & Johnson (NYSE: JNJ)'s Janssen could yield a potential $990 million in milestones plus royalties ...
more»
17:18 | 14/1/18
Concord Register
Protagonist Therapeutics, Inc. (:PTGX) closed at $19.84 after seeing 53847 shares trade hands during the most recent session.
more»
Price Alert: Protagonist Therapeutics Inc (NASDAQ:PTGX) has now crossed into technical strength -- watch the technical oscillators for momentum gaps.
more»
01:56 | 5/1/18
PR Newswire
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs.
more»
07:00 | 2/1/18
Voice Of Analysts
Protagonist Therapeutics, Inc. (PTGX) added with positive flow of 6.39% during recent week and go down so far this year; showing a decline of -5.41%.
more»
00:26 | 15/12/17
PR Newswire
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs.
more»
02:02 | 5/12/17
PR Newswire
The alfa-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist PTG-200 is currently being studied in a Phase 1 clinical trial in ...
more»